AbCellera Biologics Inc. ABCL Federal
Federal at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CurrentFederalTaxExpenseBenefit.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s federal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s federal?
- AbCellera Biologics Inc. (ABCL) reported federal of -$7.51M in Q4 2025.
- How has AbCellera Biologics Inc.'s federal changed year-over-year?
- AbCellera Biologics Inc.'s federal decreased by 62.8% year-over-year, from -$4.62M to -$7.51M.
- What is the long-term trend for AbCellera Biologics Inc.'s federal?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s federal has grown at a 0.8% compound annual growth rate (CAGR), from -$29.59M to -$30.04M.
- What does federal mean?
- The current tax expense or benefit accrued based on federal income tax regulations. It reflects the immediate tax impact of the company's domestic operational performance.